Cargando…
Developing core outcome sets for clinical trials: issues to consider
The selection of appropriate outcomes or domains is crucial when designing clinical trials in order to compare directly the effects of different interventions in ways that minimize bias. If the findings are to influence policy and practice then the chosen outcomes need to be relevant and important t...
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2012
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3472231/ https://www.ncbi.nlm.nih.gov/pubmed/22867278 http://dx.doi.org/10.1186/1745-6215-13-132 |
_version_ | 1782246556039118848 |
---|---|
author | Williamson, Paula R Altman, Douglas G Blazeby, Jane M Clarke, Mike Devane, Declan Gargon, Elizabeth Tugwell, Peter |
author_facet | Williamson, Paula R Altman, Douglas G Blazeby, Jane M Clarke, Mike Devane, Declan Gargon, Elizabeth Tugwell, Peter |
author_sort | Williamson, Paula R |
collection | PubMed |
description | The selection of appropriate outcomes or domains is crucial when designing clinical trials in order to compare directly the effects of different interventions in ways that minimize bias. If the findings are to influence policy and practice then the chosen outcomes need to be relevant and important to key stakeholders including patients and the public, health care professionals and others making decisions about health care. There is a growing recognition that insufficient attention has been paid to the outcomes measured in clinical trials. These issues could be addressed through the development and use of an agreed standardized collection of outcomes, known as a core outcome set, which should be measured and reported, as a minimum, in all trials for a specific clinical area. Accumulating work in this area has identified the need for general guidance on the development of core outcome sets. Key issues to consider in the development of a core outcome set include its scope, the stakeholder groups to involve, choice of consensus method and the achievement of a consensus. |
format | Online Article Text |
id | pubmed-3472231 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2012 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-34722312012-10-17 Developing core outcome sets for clinical trials: issues to consider Williamson, Paula R Altman, Douglas G Blazeby, Jane M Clarke, Mike Devane, Declan Gargon, Elizabeth Tugwell, Peter Trials Commentary The selection of appropriate outcomes or domains is crucial when designing clinical trials in order to compare directly the effects of different interventions in ways that minimize bias. If the findings are to influence policy and practice then the chosen outcomes need to be relevant and important to key stakeholders including patients and the public, health care professionals and others making decisions about health care. There is a growing recognition that insufficient attention has been paid to the outcomes measured in clinical trials. These issues could be addressed through the development and use of an agreed standardized collection of outcomes, known as a core outcome set, which should be measured and reported, as a minimum, in all trials for a specific clinical area. Accumulating work in this area has identified the need for general guidance on the development of core outcome sets. Key issues to consider in the development of a core outcome set include its scope, the stakeholder groups to involve, choice of consensus method and the achievement of a consensus. BioMed Central 2012-08-06 /pmc/articles/PMC3472231/ /pubmed/22867278 http://dx.doi.org/10.1186/1745-6215-13-132 Text en Copyright ©2012 Williamson et al.; licensee BioMed Central Ltd. http://creativecommons.org/licenses/by/2.0 This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Commentary Williamson, Paula R Altman, Douglas G Blazeby, Jane M Clarke, Mike Devane, Declan Gargon, Elizabeth Tugwell, Peter Developing core outcome sets for clinical trials: issues to consider |
title | Developing core outcome sets for clinical trials: issues to consider |
title_full | Developing core outcome sets for clinical trials: issues to consider |
title_fullStr | Developing core outcome sets for clinical trials: issues to consider |
title_full_unstemmed | Developing core outcome sets for clinical trials: issues to consider |
title_short | Developing core outcome sets for clinical trials: issues to consider |
title_sort | developing core outcome sets for clinical trials: issues to consider |
topic | Commentary |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3472231/ https://www.ncbi.nlm.nih.gov/pubmed/22867278 http://dx.doi.org/10.1186/1745-6215-13-132 |
work_keys_str_mv | AT williamsonpaular developingcoreoutcomesetsforclinicaltrialsissuestoconsider AT altmandouglasg developingcoreoutcomesetsforclinicaltrialsissuestoconsider AT blazebyjanem developingcoreoutcomesetsforclinicaltrialsissuestoconsider AT clarkemike developingcoreoutcomesetsforclinicaltrialsissuestoconsider AT devanedeclan developingcoreoutcomesetsforclinicaltrialsissuestoconsider AT gargonelizabeth developingcoreoutcomesetsforclinicaltrialsissuestoconsider AT tugwellpeter developingcoreoutcomesetsforclinicaltrialsissuestoconsider |